Rapport Therapeutics Announces Positive Phase 2 Results for Bipolar Mania Treatment

Key Facts

1Rapport Therapeutics announced that its Phase 2 trial of RAP-219 met primary and secondary endpoints for the treatment of bipolar mania.

Rapport Therapeutics announced that its Phase 2 trial of RAP-219 met primary and secondary endpoints for the treatment of bipolar mania. The company stated via GlobeNewswire that topline results showed statistically significant improvements in mania scores compared to a placebo, achieving a 3.1 point improvement in the YMRS total score.

The trial evaluated efficacy using the YMRS and CGI-BP scales, reaching a p-value of 0.045 for the primary results. In equity markets, RAPP closed at $28.6 on October 19, 2026, with the stock trading between a session low of $27.57 and a high of $29.1.